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Monitoring Team, Gangnam Severance Hospital, Seoul, Korea
Background: The ratio of the steady-state 24-hour area under the concentration-time curve (ssAUC24) to the MIC (AUC24/MIC) for 
vancomycin has been recommended as the preferred pharmacodynamic index. The aim of this study was to assess whether the 
calculated AUC24 (cAUC24) using the creatinine clearance (CLcr) differs from the ssAUC24 based on the individual pharmacokinetic 
data estimated by a commercial software.
Materials and Methods: The cAUC24 was compared with the ssAUC24 with respect to age, body mass index, and trough concen-
tration of vancomycin and the results were expressed as median and interquartile ranges. A correlation between the cAUC24 and 
ssAUC24 and the trough concentration of vancomycin was evaluated. The probability of reaching an AUC24/MIC of 400 or higher 
was compared between the cAUC24 and ssAUC24 for different MICs of vancomycin and different daily doses by simulation in a 
subgroup with a trough concentration of 10 mg/L and higher. 
Results: The cAUC24 was significantly lower than the ssAUC24 (392.38 vs. 418.32 mg·hr/L, P < 0.0001) and correlated weakly with 
the trough concentration (r = 0.649 vs. r = 0.964). Assuming a MIC of 1.0 mg/L, the probability of reaching the value of 400 or 
higher was 77.5% for the cAUC24/MIC and 100% for the ssAUC24/MIC in patients with a trough concentration of 10 mg/L and 
higher. If the MIC increased to 2.0 mg/L, the probability was 57.7% for the cAUC24/MIC and 71.8% for the ssAUC24/MIC at a daily 
vancomycin dose of 4,000 mg.
Conclusions: The cAUC24 using the calculated CLcr is usually underestimated compared with the ssAUC24 based on individual 
pharmacokinetic data. Therefore, to obtain a more accurate AUC24, therapeutic monitoring of vancomycin rather than a simple 
calculation based on the CLcr should be performed, and a more accurate biomarker for renal function is needed.
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Introduction
Traditionally, therapeutic monitoring of vancomycin has 
been recommended to prevent toxicity, and earlier studies es-
tablished the target peak concentration for vancomycin in the 
range of 30 to 35 mg/L, with troughs of 5 to 10 mg/L. More re-
cently, however, evidence has emerged that trough concentra-
tions of 5 to 10 mg/L might be insufficient and a higher trough 
level, i.e., exceeding 15 mg/L, has been suggested for pneu-
monia, meningitis, and for species that are more resistant [1, 2]. 
On the basis of various pharmacodynamic data, the ratio of 
the steady-state 24-hour area under the concentration-time 
curve (ssAUC24) to the MIC (ssAUC24/MIC) of 400 or higher 
has been recommended as the preferred pharmacodynamic 
index to achieve clinical effectiveness with vancomycin [3, 4]. 
Several simulation studies have suggested that the daily dose 
of vancomycin should be escalated to 4000 to 6000 mg to 
achieve the AUC24/MIC ratio of 400 or higher, and, as a result, 
a through concentration was increased to 15 to 20 mg/L [5, 6].
To obtain the AUC24 value more easily in the clinical setting, 
numerous previous studies have used the calculated AUC24 
(cAUC24) using the formula based on the CLcr (see Equation 2, 
below) to determining the vancomycin dose [3, 4, 7]. Accord-
ing to this formula, there is a possibility that the cAUC24 might 
be underestimated when the CLcr is overestimated. That 
means that a higher dose of vancomycin could be recom-
mended inappropriately when the CLcr is overestimated. Re-
cently, as the vancomycin MIC against methicillin resistant 
Staphylococcus aureus (MRSA) continues to increase, several 
studies have reported that the trough concentration of vanco-
mycin should be maintained at 20 mg/L or higher to reach a 
target value of the AUC24/MIC ratio of 400 or higher, and this 
leads to a concern that vancomycin cannot be further used for 
the treatment of MRSA due to its toxicity [6, 8, 9].
The primary objective of the current study was to assess 
whether the cAUC24 based on the CLcr differs from the esti-
mated ssAUC24 obtained from individual pharmacokinetic pa-
rameters of vancomycin in patients with normal creatinine 
concentrations by using a commercial software, the CAPCIL 
program (Simkin Inc., Gainesville, Florida, USA). Attempts 
were also made to compare these values (cAUC24, ssAUC24) 
with the trough concentration of vancomycin and thereby to 
confirm which values are more indicative of the trough con-
centration. Secondarily, we also evaluated the proportion of 
patients who reached cAUC24/MIC and ssAUC24/MIC ratios of 
400 or higher while altering the MIC and daily dose of vanco-
mycin by simulation. 
Materials and Methods
1. Subjects and collection of blood samples
This study was reviewed and approved by the Institutional 
Review Board at Gangnam Severance Hospital of Yonsei Uni-
versity Health System in Seoul, Korea (Reg. No. 3-2011-0082). 
All procedures were conducted in accordance with the guide-
lines of the Declaration of Helsinki. All data were collected 
retrospectively from patients who were receiving vancomycin 
at a single institution during a period ranging from June of 
2006 to May of 2010. We included patients who were aged 18 
years or older, patients whose serum creatinine concentration 
was lower than 1.2 mg/dL (normal range), patients who had 
vancomycin concentrations considered to have reached 
steady state (after administering more than 3 times), and pa-
tients who were given vancomycin at a dose of 1000 mg with a 
12-hour interval. Vancomycin was dispensed in a saline (100 
mL) and then intravenously infused over 1 hour. After the ad-
ministration was done more than 3 times, the concentration 
was measured. Blood samplings were done 1 hour after the 
completion of vancomycin infusion (peak) and just before the 
next infusion (trough). The concentrations of serum creati-
nine and serum cystatin C were also simultaneously mea-
sured. Other clinical and demographic data were collected 
from the medical records of the recruited patients.
Serum vancomycin concentrations were determined by flu-
orescence polarization immunoassay methods (Cobas Integra 
800 analyzer, Roche, Mannheim, Germany). The cystatin C 
concentration was measured using gold colloidal colorimetry 
(Hitachi 7600-110, Hitachi, Japan).
2.  Individual pharmacokinetic parameters of 
vancomycin
The individual pharmacokinetic parameters of vancomycin 
were derived from the CAPCIL program. The glomerular filtra-
tion rate (GFR) was estimated by serum cystatin C rather than 
serum creatinine concentration. The vancomycin clearance 
(CLvan) and volume of distribution (Vd) were estimated for 
each patient using the CAPCIL program.
3.  Individual pharmacodynamic index of vancomycin
In each patient, the ssAUC24 was estimated based on the fol-
lowing formula using individual pharmacokinetic data (Equa-
tion 1). [5]
* Equation 1: ssAUC24 = D/CLvan
 The ssAUC24 is expressed as mg ∙ hr/L, CLvan as L/hr, and D 
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is vancomycin dosage in mg/24 h. 
Besides, the cAUC24 was obtained with the following formula 
using the CLcr that has been proposed by several studies 
(Equation 2) [3, 4, 7].
* Equation 2: cAUC24 = D/[[(CLcr × 0.79) + 15.7] × 0.06]
 The cAUC24 is expressed as mg ∙ hr/L, CLcr as mL/min, and 
D is vancomycin dosage in mg/24 h.
In Equation 2, the CLcr was calculated using the Cockcroft 
and Gault formula (Equation 3) [10].
* Equation 3: CLcr (mL/min) = [140 - age (y)] × weight (kg)/
[72 × Scr (mg/dL)]
(Female: multiplying by correction factor, 0.85)
The cAUC24 value was compared with the ssAUC24 according 
to age, body mass index (BMI), and the trough concentration 
of vancomycin. The correlation between the 2 AUCs (cAUC24, 
ssAUC24) and the steady-state trough concentration of vanco-
mycin was evaluated because the trough concentration is an 
actual surrogate marker in clinical setting. 
4. Assessment of the AUC24/MIC ratio
The probability (%) of reaching a target AUC24/MIC value of 
400 or higher was compared between the cAUC24 and ssAUC24 
for different vancomycin MICs (0.5, 1.0, and 2.0 mg/L) and 
different daily vancomycin doses (2000, 2500, 3000, 3500, and 
4000 mg) by simulation. This simulation estimates the actual 
dose of vancomycin that is needed to reach a target value of 
400 for the cAUC24/MIC and ssAUC24/MIC in cases in which 
the MIC of vancomycin is actually 2.0 mg/L.
5. Statistical analysis
A statistical analysis was performed using SPSS 20 for Win-
dows (IBM, Armonk, NY, USA). Continuous data were pre-
sented as mean (standard deviation [SD]) and analyzed with 
the paired t-test if data were determined to be normally dis-
tributed or with the Wilcoxon signed-rank test for nonpara-
metric data. The nonparametric values were expressed as me-
dian and interquartile ranges (IQR). A correlation analysis 
was performed using a Pearson’s correlation coefficient (r). A 
P-value of < 0.05 was considered statistically significant.
Results
1.  Clinical characteristics and pharmacokinetic 
parameters
 A total of 596 patients (352 men and 244 women) were in-
cluded. The mean (SD) age of patients was 55.0 (16.6) years 
(range, 18-96) and the mean (SD) weight was 62.5 (13.3) kg. 
The pharmacokinetic analysis was performed using the CAP-
CIL program and included a total of 1192 vancomycin con-
centration measurements (peak and trough) in 596 patients. 
The mean (SD) Vd of vancomycin was 0.73 (0.19) L/Kg, the 
CLvan was 5.02 (1.93) L/hr, and the half-life (T1/2) was 6.92 
(2.86) hours (Table 1). 
2. Pharmacodynamic index
 The ssAUC24 was significantly higher than the cAUC24: the 
median (IQR) values were 418.32 (330.35, 546.19) and 392.38 
(322.63, 486.73), respectively (P < 0.0001; Table 2). Patients 
were also divided into subgroups based on age, BMI, and 
trough concentration. The cAUC24 was found to be relatively 
lower than the ssAUC24 in almost all subgroups. In particular, 
in older patients with a higher trough concentration, a higher 
degree of difference between the ssAUC24 and cAUC24 was ob-
served (Table 2). The ssAUC24 showed a stronger correlation 
with the trough concentration than the cAUC24 (r = 0.964 and 
r = 0.649) (Fig. 1A, 1B).
3. Assessment of the AUC24/MIC 
Assuming that the MIC of vancomycin against MRSA was 1.0 
mg/L, the number of patients who reached the target cAUC24/
MIC and ssAUC24/MIC values of 400 or higher was 286 of 576 
(48.0%) and 322 of 576 (54.0%), respectively. In patients with a 
trough concentration of 10 mg/L and higher (227 patients), 
the percentage of those who reached the cAUC24/MIC and 
ssAUC24/MIC values of 400 or higher was 77.5% (n = 176) and 
Table 1. Demographic characteristics and pharmacokinetic parameters 
of the patients
Mean (SD)
Sex (Male : Female) (Number) 352 : 244
Age (years) 55.0 (16.6)
Body weight (kg) 62.5 (13.3)
Serum creatinine concentration (mg/dL) 0.78 (0.19)
Serum cystatin-C concentration (mg/L) 0.98 (0.33)
Vancomycin peak concentration (mg/L) 33.88 (9.87)
Vancomycin trough concentration (mg/L) 10.04 (6.99)
Volume of distribution (Vd, L/Kg) 0.73 (0.19)
Vancomycin clearance (CLvan, L/hr) 5.02 (1.93)
Half life (T1/2, hour) 6.92 (2.86)
Calculated creatinine clearance (CLcr, mL/min) 94.49 (40.83)
SD, standard deviation.
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Table 2. Comparison of the calculated AUC24 (cAUC24) with 24-hour steady-state AUC (ssAUC24) according to age, BMI, and the trough concentration of 
vancomycin
Group
Number
(%)
cAUC24 (mg·hr/L)
[Median (IQR)]
ssAUC24 (mg·hr/L)
[Median (IQR)]
P-valuea
Age group (year)
< 30  58 (9.7) 292.26 (240.30, 357.09) 320.39 (250.37, 423.48) 0.0007
30-39    61 (10.2) 309.41 (259.58, 357.64) 321.32 (274.36, 441.76) 0.0007
40-49    95 (15.9) 345.52 (293.99, 388.74) 349.91 (303.10, 452.21) 0.0165
50-59 125 (21.0) 398.71 (340.89, 442.20) 418.69 (336.96, 515.45) 0.0013
60-69 131 (22.0) 429.13 (365.03, 511.71) 427.20 (361.96, 579.44) 0.0391
70-79   98 (16.4) 497.94 (433.16, 569.65) 523.98 (427.03, 629.11) 0.0114
≥ 80 28 (4.7) 619.89 (521.13, 739.49) 755.28 (563.89, 848.44) 0.0139
BMI group (kg/m2)
< 18.5    63 (10.6) 458.20 (382.77, 563.33) 488.99 (362.84, 635.53) 0.0897
18.5 ≤ 23 254 (42.6) 405.43 (337.05, 499.17) 413.63 (333.51, 539.80) 0.0012
23 ≤ 25 123 (20.6) 377.48 (320.17, 467.79) 422.06 (330.40, 538.05) 0.0001
25 ≤ 30 126 (21.1) 373.70 (301.94, 456.27) 396.12 (313.82, 518.44) < 0.0001
≥30 30 (5.0) 295.34 (238.73, 419.43) 372.98 (249.42, 549.86) < 0.0001
Trough conc. (mg/L)
< 5 132 (22.2) 298.20 (258.68, 341.89) 279.03 (239.42, 312.13) 0.0011
5 ≤ 10 237 (39.8) 381.93 (334.69, 436.51) 386.23 (344.36, 422.70) 0.5018
10 ≤ 15 120 (20.1) 455.47 (388.80, 539.22) 523.14 (475.57, 561.70) < 0.0001
15 ≤ 20 55 (9.2) 496.72 (409.42, 577.79) 646.91 (591.10, 691.37)  < 0.0001
≥20 52 (8.7) 580.10 (495.50, 682.68) 853.03 (801.28, 1018.68) < 0.0001
Total 596 (100) 392.38 (322.63, 486.73) 418.32 (330.35, 546.19) < 0.0001
AUC, area under the curve; BMI, body mass index; conc., concentration; CLcr, creatinine clearance; CLvan, vancomycin clearance; Scr, serum creatinine.
cAUC24 = Daily dose (mg)/[(CLcr (mL/min) x 0.79) + 15.7] x 0.06. ssAUC24 = Daily dose (mg)/CLvan (L/hr). CLcr (mL/min) = [140-age (y)] x weight (kg)/[72 x Scr (mg/
dL)].(Female: multiplying by correction factor, 0.85).
aData analyzed with the Wilcoxon signed-rank test.
y = 26.869x + 192.14
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Figure 1. Relationship between the steady-state 24-hour AUC (ssAUC24) and steady-state trough concentration of vancomycin (A), and between the 
calculated AUC (cAUC24) and steady-state trough concentration of vancomycin (B).
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100%, respectively. However, among patients with a trough 
concentration from 5 to less than 10 mg/L, 50% and lesser 
achieved the target AUC24/MIC value.
4. Simulation
Assuming that vancomycin is administered at a daily dose 
of 2000, 2500, 3000, 3500, and 4000 mg and the MIC of vanco-
mycin against MRSA is 0.5, 1.0, and 2.0 mg/L, we performed a 
simulation to evaluate the proportion of patients whose 
cAUC24/MIC and ssAUC24/MIC ratios reached the target value 
of 400 or higher. When the MIC of vancomycin was 2.0 mg/L, 
the probability (%) of reaching the target cAUC24/MIC and 
ssAUC24/MIC values was less than 40% in patients with a 
trough concentration of 10 to 15 mg/L at a daily vancomycin 
dose of 4000 mg. In patients with a trough concentration of 15 
to 20 mg/L, the probability (%) of reaching the target ssAUC24/
MIC and cAUC24/MIC values of 400 or higher was 71.8% and 
57.7%, respectively, even at a daily vancomycin dose of 4000 
mg (Fig. 2, Table 3). 
Discussion
The appropriate assessment of renal function and the result-
ing adjustment of the dose are mandatory in antibiotics such 
as vancomycin, which are mainly excreted from the kidney. 
The effective therapeutic range of vancomycin has been main-
ly recommended to be from 5 to 10 mg/L based on the trough 
concentration in consideration of the effect and safety. In re-
cent years, however, depending on the sites of infection, the 
concentration has been recommended to be from 10 to 15 
mg/L in patients with endocarditis and from 15 to 20 mg/L in 
those with pneumonia or meningitis. It has also been recom-
mended that a therapeutic range be maintained at approxi-
mately 15 to 25 mg/L for the continuous intravenous infusion 
[1, 2]. According to most of the recent studies, the ssAUC24/
MIC ratio rather than %time > MIC has been proposed as the 
pharmacodynamic index indicating the clinical responses of 
vancomycin, and the target AUC24/MIC value is recommend-
ed to be maintained at the level of 400 or higher [3, 4]. Based 
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Figure 2. Probability (%) of reaching target ssAUC24/MIC (A) and cAUC24/MIC (B) values of 400 or higher for different MICs (0.5, 1.0, and 2.0 mg/L) and 
daily vancomycin doses (2,000, 2,500, 3,000, 3,500, and 4,000 mg) by simulation in patients with a trough concentration of 15 to 20 mg/L.
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Table 3. Probability (%) of reaching a target AUC24/MIC value of 400 or higher for different MICs and daily vancomycin doses by simulation in patients 
with a trough concentration of 15 to 20 mg/L. 
Vancomycin dose 
(mg/d)
% of cAUC24/MIC ≥400 % of ssAUC24/MIC ≥ 400
MIC = 0.5 MIC = 1.0 MIC = 2.0 MIC = 0.5 MIC = 1.0 MIC = 2.0
2,000 100 78.2 0 100 100    3.6
2,500 100 94.9    5.1 100 100 11.5
3,000 100 98.9 25.6 100 100 34.4
3,500 100 100 36.5 100 100 48.2
4,000 100 100 57.7 100 100 71.8
AUC, area under the curve; MIC, minimal inhibitory concentration; cAUC24, calculated AUC; ssAUC24, steady state 24-hour AUC.
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on this target, several studies have been conducted to assess 
the validity of the treatment dose of vancomycin and to adjust 
it [5, 6, 9]. However, in actual clinical settings, it can be difficult 
to obtain multiple serum vancomycin concentrations to de-
termine the accurate AUC24. Therefore, most of the studies 
have obtained the value of the cAUC24 using the formula 
based on the CLcr (Equation 2) [3-5, 7]. However, according to 
some previous studies including ours [11, 12], serum cystatin 
C level rather than serum creatinine level is better indicative 
of the renal function. Therefore, we used serum cystatin C 
rather than serum creatinine to estimate individual GFR in the 
CAPCIL program, which is one of the applications to monitor 
drug therapy [13-15]. Finally, it is necessary to identify a new 
marker that would better reflect the renal function compared 
with the serum creatinine level or CLcr. Cystatin C may be 
considered as a good candidate for a new marker in patients 
with a normal creatinine concentration [11, 16-19]. Some au-
thors have also noted that there is a tendency to overestimate 
the CLcr in elderly people or those with a smaller muscle 
mass [16-20]. Therefore, there is a possibility that the formula 
(Equation 2) might conversely underestimate the cAUC24 and, 
as a result, a higher dose of vancomycin might be recom-
mended inappropriately.
In particular, the MIC of vancomycin against MRSA has 
been recently observed to be gradually increasing, which has 
led to the opinions that vancomycin is no longer necessary [5, 
9, 21]. This is not only because a higher dose of vancomycin 
should be administered at a daily dose of up to 5000 to 6000 
mg to maintain the AUC24/MIC of 400 or higher but also be-
cause the actual administration would be difficult because of 
adverse effects such as nephrotoxicity in these cases. Further-
more, we also observed the MIC of vancomycin, by micro-
broth dilution method using Vitek 2 system (bioMerieux, Mar-
cy 1’Etoile, France), to have gradually increased at our 
institution during a period from 2007 to 2010 (Fig. 3). There-
fore, we attempted to assess whether the cAUC24 calculated 
from the CLcr was different from the ssAUC24 based on the in-
dividual pharmacokinetic parameters of vancomycin derived 
from a commercial software. We also attempted to investigate 
how much vancomycin was actually needed to reach the tar-
get AUC24 in a higher MIC by simulation. Finally, we examined 
which of the 2 AUCs (cAUC24 or ssAUC24) was more correlated 
with the trough concentration of vancomycin. The trough con-
centration may be used as a surrogate marker for the AUC; 
therefore, the analysis of the correlation between the 2 AUCs 
and the trough concentration is important to determine the 
administration dose of vancomycin.
As we expected, the cAUC24 was found to be significantly 
lower compared with the ssAUC24. In older patients with a 
higher trough concentration, there was a higher discrepancy 
between the 2 AUCs. This means that the CLcr could be over-
estimated and the serum creatinine concentration could not 
reliably reflect the renal function in those subgroups. Accord-
ingly, it is possible that the doses of vancomycin suggested by 
several studies based on the cAUC24 were too high [5, 9]. In 
particular, in regard to the correlation with the trough concen-
tration, which might vary depending on the actual renal func-
tion of patients, the ssAUC24 showed a closer relationship with 
the trough concentration than the cAUC24 (Fig. 1A, 1B). Some 
clinicians have decreased the extent of therapeutic drug mon-
itoring of vancomycin because there is little evidence to sup-
port a relationship between serum concentrations and effica-
cy and toxicity [20, 22]. However, because it may be difficult to 
determine the accurate AUC24 in the clinical setting, trough 
concentration monitoring can be effectively used as a surro-
gate marker for the AUC. 
As shown in our study, assuming that the MIC of vancomy-
cin against MRSA was 1.0 mg/L, the number of patients who 
reached the target cAUC24/MIC and ssAUC24/MIC values of 
400 or higher were 286 of 576 (48.0%) and 322 of 576 (54.0%), 
respectively. In the subgroup with a trough concentration 
from 5 to less than 10 mg/L (237 patients), the probability of 
reaching a target AUC24/MIC of 400 or higher was about 40% 
both for ssAUC24 and cAUC24. Therefore, it is not surprising 
that patients with a trough concentration of less than 10 mg/L 
were likely not to respond to vancomycin treatment. However, 
in the subgroup with a trough concentration of 10 mg/L and 
Figure 3. Percent distribution of the vancomycin MIC (by microbroth di-
lution method using Vitek 2 system [bioMerieux, Marcy 1’Etoile, France]) 
against MRSA isolated from July 2007 to June 2010 at the Gangnam 
Severance Hospital.
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higher (227 patients), the percentage of patients reaching tar-
get cAUC24/MIC and ssAUC24/MIC values was 77.5% (176 of 
227) and 100%, respectively. These results are quite accept-
able but the daily dose of vancomycin should be increased to 
2500 mg to increase the proportion of patients reaching the 
target cAUC24/MIC value to more than 90%. In other words, 
there is a possibility that a higher dose of vancomycin could 
be recommended inappropriately if the cAUC24 was used as 
the pharmacodynamic index. In a recent consensus review, it 
was recommended that the trough concentration should al-
ways be maintained above 10 mg/L to avoid development of 
resistance, and for a pathogen with a MIC of 1 mg/L, the 
trough concentration would have to be at least 15 mg/L to 
achieve the target AUC24/MIC value of 400 [23]. Using the 
Monte Carlo simulation, Mohr and Murray determined that 
the probability of achieving an AUC24/MIC of 400 or higher 
would be 100% with a MIC of 0.5 mg/L, 40% to 60% with a 
MIC of 1.0 mg/L, and 0% with a MIC of 2.0 mg/L [24]. Del Mar 
Fernández de Gatta Garcia et al. reported that a probability of 
90% of reaching a target AUC24/MIC value of 400 with a MIC 
of 1 mg/L would require a daily vancomycin dose of 3 to 4 g [5, 
25]. However, in the present study, if we used the ssAUC24 as 
the pharmacodynamic index rather than the cAUC24, a daily 
vancomycin dose of 2 g would be enough to reach the target 
value at a MIC of 1 mg/L. 
However, the results were different with a MIC of 2.0 mg/L. 
The probability of reaching target cAUC24/MIC and ssAUC24/
MIC values was 0% in the subgroup with a trough concentra-
tion from 10 to less than 15 mg/L. Even in the subgroup with a 
higher trough concentration from 15 to less than 20 mg/L, the 
probability was 0% and 3.6%, respectively. Therefore, the daily 
dose of vancomycin should be increased to achieve a satisfac-
tory clinical effect with a MIC of 2.0 mg/L. The simulation 
showed that the probability of reaching target cAUC24/MIC 
and ssAUC24/MIC values in patients with a trough concentra-
tion from 10 to 15 mg/L was less than 40% even at a daily van-
comycin dose of 4000 mg (Table 3). This means that the 
trough concentration of 10 to 15 mg/L would not be accept-
able with a MIC of 2.0 mg/L. The probability of reaching target 
cAUC24/MIC and ssAUC24/MIC values in patients with a 
trough concentration of 15 to 20 mg/L was 57.7% and 71.8%, 
respectively, at a daily vancomycin dose of 4000 mg (Table 3). 
A high vancomycin dose is certainly needed to reach a target 
AUC24/MIC value with a MIC of 2.0 mg/L; however, a higher 
dose could be recommended when the cAUC24/MIC ratio was 
used for determining the daily dose of vancomycin. 
Likewise, an extremely high dose of vancomycin can be in-
appropriately recommended when we use the cAUC24/MIC 
ratio based on the serum creatinine concentration. Instead, it 
would be more reasonable to monitor the trough concentra-
tion as a surrogate marker in the actual clinical setting. As 
shown by our study, the MIC of 1.0 mg/L or higher allows to 
predict that the satisfactory goals of the pharmacodynamic 
index may be achieved if the trough concentration is main-
tained at the level of 10 mg/L and higher.
Our study has several limitations. First, we could not directly 
confirm the correlation between the ssAUC24/MIC ratio and 
clinical outcome. In other words, we could not confirm 
whether the treatment effects clinically vary between patients 
with an ssAUC24/MIC value of 400 or higher and those with a 
cAUC24/MIC value of less than 400. In addition, we could not 
analyze the MICs of vancomycin against MRSA isolated from 
each patient. Therefore, further studies are needed to examine 
the correlations between the MICs of vancomycin against 
MRSA isolated from each patient and ssAUC24/MIC and 
cAUC24/MIC, and to directly confirm the clinical outcomes. 
Moreover, several errors that could affect the pharmacody-
namic index might have occurred at each step of the thera-
peutic drug monitoring (TDM) process, and they could not be 
completely controlled because of a retrospective design of the 
study. It is possible that the Cockcroft and Gault method 
might have caused the differences between the cAUC24 and 
ssAUC24.
In conclusion, several studies have shown that the AUC24/
MIC ratio is a pharmacodynamic index that reflects the effects 
of vancomycin [3-6, 9]. However, a more thorough study is 
needed to determine the administrative dose of vancomycin 
based on the cAUC24/MIC based on the CLcr. Despite the 
above limitations, our results showed that the cAUC24 was 
clearly underestimated compared with the estimated ssAUC24 
based on individual pharmacokinetic data. Accordingly, it 
should be considered that a higher dose of vancomycin could 
be recommended inappropriately when the cAUC24 was used. 
Therefore, a more accurate clinical outcome study should be 
performed to evaluate the appropriate dose of vancomycin. 
Finally, to obtain a more accurate AUC24, therapeutic monitor-
ing of vancomycin rather than simple calculation based on 
the CLcr should be performed, and a more accurate biomark-
er of the renal function is needed.
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